TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22479361
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to daily low-dose vitamin A (5000 IU) for 15 days.
Study: 19017676
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose exercise programme (60 min/day) conducted whilst standing
Study: 19017676
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose exercise programme (30 min/day) primarily conducted whilst seated/supine
Study: 17515696
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet HCl (90 mg) following a high-fat, high-caloric meal
Study: 17515696
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet HCl (90 mg) following a low-fat, low-caloric meal
Study: 17515696
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet HCl (90 mg) under fasting conditions
Study: 17515696
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet HCl (90 mg) following high-fat meal
Study: 17515696
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet HCl (90 mg) following low-fat meal
Study: 17515696
Drug: Cinacalcet HCl
Normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet HCl (90 mg) across all treatment conditions
Study: 10869738
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (no boost)
Study: 9184703
Drug: Glimepiride 3
Normalized name: glimepiride 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 3 mg twice daily
Study: 9184703
Drug: Glimepiride 6
Normalized name: glimepiride 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 6 mg once daily
Study: 1589410
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray formulation without STDHF
Study: 1589410
Drug: Nasal formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal formulations containing 3% (w/v) of STDHF
Study: 1589410
Drug: Nasal formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal formulations containing 1.65% (w/v) of STDHF
Study: 1589410
Drug: Nasal formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal formulations containing 1.2% (w/v) of STDHF
Study: 1589410
Drug: Nasal formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal formulations containing 0.8% (w/v) of STDHF
Study: 1589410
Drug: All STDHF-containing
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All STDHF-containing sprays
Study: 27893539
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) treatment
Study: 26131788
Drug: Mobile training
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile training video for chemical nerve agent scenario
Study: 21134121
Drug: 5u/mL BTX‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5u/mL BTX‐A
Study: 12948920
Drug: 0.005% calcipotriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% calcipotriol alone once daily (monotherapy)
Study: 12948920
Drug: 0.004% calcipotriol/0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.004% calcipotriol/0.01% clobetasol propionate as a premixed ointment once daily (combination therapy)
Study: 30649257
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without any further treatment)
Study: 29562486
Drug: Ice pack
Normalized name: Ice Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice pack therapy
Study: 27573936
Drug: THCV (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: THCV (5 mg twice daily)
Study: 27573936
Drug: CBD (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (100 mg twice daily)
Study: 27573936
Drug: Combination treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatments (1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily) and 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily))
Study: 23809278
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 1.5 mg + meloxicam 15 mg
Study: 20884177
Drug: Nifedipine CR
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine CR 40 mg
Study: 20884177
Drug: Diltiazem R
Normalized name: R-348
DrugBank: R-348 (DB06321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem R 100 mg
Study: 18203086
Drug: Latanoprost-timolol maleate
Normalized name: latanoprost / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost-timolol maleate fixed combination (LTFC) administered at 8 PM (Group 1)
Study: 18203086
Drug: Latanoprost-timolol maleate
Normalized name: latanoprost / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost-timolol maleate fixed combination (LTFC) administered at 8 AM (Group 2)
Study: 18203086
Drug: Latanoprost therapy
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost therapy alone (Control)
Study: 9524791
Drug: Intramuscular meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular meloxicam (15 mg) on Day 1 followed by oral meloxicam (15 mg/day) for 7 days
Study: 9524791
Drug: Intramuscular piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular piroxicam (20 mg) on Day 1 followed by oral piroxicam (20 mg/day) for 7 days
Study: 3513719
Drug: Three injection
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injection regimen (delaying evening intermediate acting insulin to bedtime)
Study: 3513719
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin regimen (evening intermediate acting insulin before the evening meal)
Study: 30585526
Drug: Primary radical
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary radical prostatectomy (RP) with extended pelvic lymph-node dissection and adjuvant or salvage radiation therapy (RT) and/or androgen deprivation therapy (ADT) if deemed necessary.
Study: 30585526
Drug: Primary radiation
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary radiation treatment (RT) plus androgen deprivation treatment (ADT).
Study: 20406214
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (200 ml t.i.d. for 5 days)
Study: 17965148
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg single-dose
Study: 10368494
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol (2 mg twice daily)
Study: 10368494
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (2 mg twice daily)
Study: 2015735
Drug: Temazepam, 30
Normalized name: Temazepam, 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam, 30 mg
Study: 7089798
Drug: Coffee (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (active drug)
Study: 29781308
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol ointment
Study: 18437470
Drug: Encouragement to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encouragement to resume daily physical activity with standardized advice and individualized activity goals
Study: 18437470
Drug: Encouragement to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encouragement to resume daily physical activity
Study: 11408507
Drug: HEC (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC (epirubicin 100 mg/m², cyclophosphamide 830 mg/m²; day 1 every 3 weeks)
Study: 11408507
Drug: EC (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC (epirubicin 60 mg/m², cyclophosphamide 500 mg/m²; day 1 every 3 weeks)
Study: 11408507
Drug: CMF (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (oral cyclophosphamide for six cycles)
Study: 9208358
Drug: Captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75 mg thrice daily)
Study: 2626336
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (50 mg/kg)
Study: 386715
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g L-tryptophan daily
Study: 25049195
Drug: Treatment focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment focusing on weight and behavioral symptoms
Study: 25049195
Drug: Treatment focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment focusing solely on improving QoL
Study: 21056284
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (OJ) concentrate, 750 mL/day for 60 days
Study: 15699477
Drug: gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gefitinib 250 mg/d
Study: 15699477
Drug: gefitinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: gefitinib 500 mg/d
Study: 9032097
Drug: Intraperitoneal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal insulin therapy (IP)
Study: 7822993
Drug: Education on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education on diagnostic tests, chart audit, and feedback provided twice a week for first and second year residents; peer-review strategy for staff.
Study: 3555162
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg epinephrine added to hyperbaric spinal bupivacaine
Study: 25135124
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of oral melatonin administered at 9:00 pm for four consecutive days
Study: 25135124
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 9:00 pm for four consecutive days
Study: 19933916
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy (3 or 4 cycles)
Study: 16157231
Drug: Gabapentin (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (0 and 600 mg/day)
Study: 1932484
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine (10 mg bolus followed by a constant infusion of 3.2 mg/h)
Study: 1932484
Drug: Placebo (similarly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similarly administered)
Study: 7136659
Drug: Colostrum, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrum, 20 ml three times a day along with nursery formula
Study: 30430667
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation therapy for 20 min and oral health education for 15 min before periodontal treatment once per week for 4 wk
Study: 30430667
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education only for the same duration
Study: 30430667
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation therapy
Study: 30430667
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education only
Study: 26898569
Drug: Mesalazine modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine modified-release tablets (MR group, n = 123)
Study: 26898569
Drug: Mesalazine enteric-coated
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine enteric-coated tablets (EC group, n = 128)
Study: 26898569
Drug: Mesalazine modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine modified-release tablets (MR group)
Study: 26898569
Drug: Mesalazine enteric-coated
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine enteric-coated tablets (EC group)
Study: 23034968
Drug: HFrAA (6.77
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFrAA (6.77 g of a mixture of 5 essential amino acids 3 times/d)
Study: 23034968
Drug: HFr (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFr (3 g fructose · kg(‐1) · d(‐1) and maltodextrin placebo 3 times/d)
Study: 15015000
Drug: Passive warming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive warming to rectal temperature of 39.5 degrees C
Study: 11606169
Drug: Euglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (blood glucose approximately 6 mmol/l)
Study: 11606169
Drug: Hyperglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (blood glucose approximately 14 mmol/l)
Study: 8033186
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml Oolong tea extract (OTE) solution in 0.2% ethanol before and after every intake of food and before sleeping at night
Study: 8033186
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml Oolong tea extract (OTE) solution
Study: 2756357
Drug: Clindamycin and
Normalized name: clindamycin and benzoyl peroxide KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin and gentamicin (administered preoperatively as a single bolus infusion)
Study: 2756357
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered preoperatively as a single bolus infusion)
Study: 791330
Drug: labetalol (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (average daily dose about 600 mg)
Study: 18473792
Drug: DG17 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: DG17 with sodium bicarbonate solution
Study: 18473792
Drug: DG17 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: DG17 with low-dose ritonavir
Study: 1384898
Drug: Cytotoxic/G-CSF mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic/G-CSF mobilization
Study: 29389579
Drug: Ankascin 568
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankascin 568 plus (500 mg/day)
Study: 26995799
Drug: SoluMatrix diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoluMatrix diclofenac 35 mg
Study: 26995799
Drug: SoluMatrix diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoluMatrix diclofenac 18 mg
Study: 26995799
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg loading dose followed by 200 mg twice daily
Study: 22892735
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL 1% peracetic acid (PAA)
Study: 22892735
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL 17% EDTA
Study: 22892735
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL 2.5% NaOCl + 2.5 mL 17% EDTA
Study: 22892735
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL 0.5% PAA
Study: 18460399
Drug: Teeth brushing
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teeth brushing plus tongue cleaning using a high speed vacuum ejector and irrigation with 20 ml antibacterial mouthwash
Study: 18460399
Drug: Daily tongue
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tongue scraping
Study: 12451982
Drug: Tablet Tongmaijiangzhi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Tongmaijiangzhi (TTMJZ) 4 tablets, tid for 8 weeks
Study: 12451982
Drug: Zocor 5
Normalized name: Zocor 5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zocor 5 mg, qd for 8 weeks
Study: 10613415
Drug: 117 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 117 mg/day of vitamin C during repletion phase
Study: 10613415
Drug: 9 mg/day
Normalized name: EMSAM 9 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg/day of vitamin C during depletion phase
Study: 24093506
Drug: Conventional balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional balance training according to physical therapy guidelines
Study: 15026295
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence tracked with electronic cap monitors for 24 weeks
Study: 10770980
Drug: High-fiber group
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber group (13.5 g per day of wheat-bran fiber)
Study: 10770980
Drug: Low-fiber group
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber group (2 g per day of wheat-bran fiber)
Study: 9007490
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 0.25 mg/kg/12 h
Study: 8024293
Drug: Topical inhaled
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical inhaled corticosteroids (beclomethasone dipropionate 400 micrograms daily)
Study: 3113712
Drug: Dibromomannitol (DBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dibromomannitol (DBM) at a dose of 4 mg/kg
Study: 23028103
Drug: cinacalcet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinacalcet plus low‐dose vitamin D (≤ 6 µg/week of intravenous paricalcitol equivalent)
Study: 16774847
Drug: Self-selected treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected treatment (n=180)
Study: 9539495
Drug: Abciximab (GP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (GP IIb/IIIa blocker), administered as a bolus and 12-hour infusion
Study: 9539495
Drug: Abciximab (GP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (GP IIb/IIIa blocker)
Study: 9539495
Drug: Low-dose, weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, weight-adjusted heparin regimen, early vascular sheath removal, and elimination of routine postprocedural heparinization
Study: 9539495
Drug: Abciximab (24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (24-hour preprocedural infusion)
Study: 9539495
Drug: Other GP
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other GP IIb/IIIa inhibitors (eptifibatide, lamifiban, tirofiban)
Study: 31665455
Drug: Liraglutide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (3 mg SQ daily)
Study: 26806566
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (two sessions of live music-based relaxation exercises)
Study: 22842777
Drug: Supervised implementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised implementation of the Oral health care Guideline for Older people in Long‐term care Institutions (OGOLI)
Study: 12701987
Drug: Synthetic formulation
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic formulation of BNP (nesiritide)
Study: 11045888
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sumatriptan orally at 0700 h
Study: 11045888
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sumatriptan orally at 0700 h and 0100 h
Study: 11045888
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sumatriptan orally at 1300 h
Study: 8370699
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g ethanol/kg wt
Study: 8370699
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ethanol/kg wt
Study: 8370699
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g ethanol/kg wt
Study: 3522509
Drug: Piracetam (3300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (3300 mg daily for 12 weeks)
Study: 29917140
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy of tamoxifen followed by exemestane
Study: 29917140
Drug: Exemestane monotherapy
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane monotherapy
Study: 19176089
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTXA) injection into bilateral rectus muscle
Study: 12807340
Drug: Hypericum cream
Normalized name: Hypericum oil
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum cream
Study: 12807340
Drug: Hypericum cream
Normalized name: Hypericum oil
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum cream and vehicle
Study: 27362506
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d DHA
Study: 26059084
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) + aspirin (ASA)
Study: 17952272
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (G1) - 70.5 (45.1‐87.5) units of insulin/day
Study: 17952272
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (G2) - 2 (0.6‐14.1) units of insulin/day